Lanthanum Carbonate
Title: Lanthanum Carbonate
CAS Registry Number: 587-26-8
CAS Name: Carbonic acid lanthanum(3+) salt (3:2)
Additional Names: lanthanum sesquicarbonate
Trademarks: Fosrenol (Shire); Foznol (Shire)
Molecular Formula: C3La2O9
Molecular Weight: 457.84
Percent Composition: C 7.87%, La 60.68%, O 31.45%
Line Formula: La2(CO3)3
Literature References: Binds dietary phosphate to reduce hyperphosphatemia in patients with chronic renal failure. Occurs in various hydrated forms. Prepn of hydrated forms: M. L. Salutsky, L. L. Quill, J. Am. Chem. Soc. 72, 3306 (1950); and use of hydrated pharmaceutical compositions: B. A. Murrer, N. A. Powell, US 5968976 (1999 to AnorMed Inc.). Crystal structure of octahydrate: D. B. Shinn, H. A. Eick, Inorg. Chem. 7, 1340 (1968). Soly equilibrium of octahydrate: D. Ferri, F. Salvatore, Acta Chem. Scand. 37, 531 (1983). Clinical trial in hyperphosphatemia: M. S. Joy, W. F. Finn, Am. J. Kidney Dis. 42, 96 (2003). Review of clinical development: T. S. Harrison, L. J. Scott, Drugs 64, 985-996 (2004); and clinical efficacy: F. Albaaj, A. J. Hutchison, Expert Opin. Pharmacother. 6, 319-328 (2005).
Therap-Cat: In treatment of hyperphosphatemia.
Keywords: Antihyperphosphatemic.

Others monographs:
RhodopsinSaponinsSodium ThiocarbonateMesoridazine
DigitoxoseSelenium SulfidesBismuth IodideKinoprene
CyclohexylcarbinolLead PhosphateSodium HydrosulfiteHemi-Dewar Biphenyl
Tung OilIsoflurophatePhosphorus OxybromideCyacetacide
©2016 DrugLead US FDA&EMEA